A system for treating high-hardness concentrated brine in the pharmaceutical industry

Abstract

The utility model provides a system for processing high hardness concentrated salt water of pharmaceutical industry, including front end processing unit, electrochemistry removes hard unit, tubular membrane equipment, weak acid resin removes hard unit and evaporimeter. Front end processing unit is used to pretreatment to pharmaceutical wastewater, electrochemistry removes hard unit with front end processing unit connection, and electrochemistry removes hard unit produces flocculating agent for gathering suspended particles through electrode, tubular membrane equipment is used to filter to the pharmaceutical wastewater after electrochemistry removes hard unit processing, weak acid resin removes hard unit is used to remove calcium magnesium ion to the pharmaceutical wastewater after tubular membrane equipment filtration, evaporimeter is used to evaporate to the concentrated water of weak acid resin removes hard unit export. The utility model provides a system for processing high hardness concentrated salt water of pharmaceutical industry, aims at can solve the problem that evaporimeter heat exchange pipe is scaled seriously in the process of treating pharmaceutical wastewater in prior art and leads to evaporimeter life reduction.

Description

Technical Field

[0001] This utility model belongs to the field of wastewater treatment technology, specifically relating to a system for treating high-hardness concentrated brine in the pharmaceutical industry. Background Technology

[0002] The pharmaceutical industry is one of my country's important industries. Based on processes, the pharmaceutical industry is divided into synthetic pharmaceuticals and fermentation pharmaceuticals, both of which generate high-concentration wastewater, high-salinity wastewater, and low-concentration wastewater. High-concentration and high-salinity wastewater contain various substances such as DMF, acetone, and benzene, with complex compositions and a certain degree of toxicity. Therefore, pharmaceutical wastewater needs to be treated before being discharged.

[0003] In existing technologies, a combination of processes including "pretreatment + biochemical treatment + ultrafiltration + reverse osmosis + chemical softening + high-pressure reverse osmosis + evaporation system" is used to treat pharmaceutical wastewater. During the treatment of pharmaceutical wastewater, the high-pressure reverse osmosis concentrate contains a large amount of calcium and magnesium ions and high levels of organic matter (hardness reaches 900 mg / L, chemical oxygen demand reaches 3000 mg / L), leading to severe scaling on the evaporator heat exchange tubes, affecting the evaporator's service life and resulting in poor practicality. Utility Model Content

[0004] This invention provides a system for treating high-hardness concentrated brine in the pharmaceutical industry, aiming to solve the problem of severe scaling of evaporator heat exchange tubes leading to reduced evaporator lifespan in the process of treating pharmaceutical wastewater in the prior art.

[0005] To achieve the above objectives, the technical solution adopted by this utility model is: to provide a system for treating high-hardness concentrated brine in the pharmaceutical industry, comprising:

[0006] The front-end processing unit is used for pretreatment of pharmaceutical wastewater;

[0007] An electrochemical hardening removal unit is connected to the front-end processing unit, and the electrochemical hardening removal unit generates flocculants for agglomerating suspended particles through electrodes;

[0008] A tubular membrane device is connected to the electrochemical hardening unit, the tubular membrane device including a filter membrane for cross-flow filtration, used to filter pharmaceutical wastewater treated by the electrochemical hardening unit;

[0009] A weak acid resin hardening unit is connected to the tubular membrane equipment and is used to remove calcium and magnesium ions from pharmaceutical wastewater filtered by the tubular membrane equipment.

[0010] An evaporator, connected to the weak acid resin hardening unit, is used to evaporate the concentrated water discharged from the weak acid resin hardening unit.

[0011] In one possible implementation, the front-end processing unit includes:

[0012] The raw material container is used to hold pharmaceutical wastewater awaiting treatment.

[0013] An ozone catalytic oxidation unit is connected to the original liquid container and is used to oxidize the organic matter in the pharmaceutical wastewater to be treated.

[0014] In one possible implementation, the ozone catalytic oxidation unit includes:

[0015] An ozone catalytic oxidation tank is connected to the raw liquid container and to an ozone source. The ozone catalytic oxidation tank is used to carry out catalytic oxidation reactions.

[0016] An ozone effluent tank is connected to the ozone catalytic oxidation tank, and the ozone effluent tank is used to temporarily store the effluent from the ozone catalytic oxidation tank.

[0017] In one possible implementation, the system for treating high-hardness concentrated brine in the pharmaceutical industry further includes a sludge dewatering machine connected to the electrochemical hardening unit and the ozone effluent tank.

[0018] In one possible implementation, the system for treating high-hardness concentrated brine in the pharmaceutical industry further includes:

[0019] An electrodialysis unit is connected to the weak acid resin hardening unit. The electrodialysis unit includes a concentrate tank, a desalination tank, and an electrode tank; the concentrate tank is connected to the evaporator.

[0020] The reverse osmosis unit is connected to the freshwater tank and is used to receive freshwater and recycle it.

[0021] In one possible implementation, the system for treating high-hardness concentrated brine in the pharmaceutical industry further includes:

[0022] The first intermediate water storage tank is located between the electrochemical hardening unit and the tubular membrane device, and is used to store the effluent from the electrochemical hardening unit or the influent from the tubular membrane device.

[0023] The second intermediate water storage tank is located between the tubular membrane equipment and the weak acid resin hardening unit, and is used to store the effluent from the tubular membrane equipment or the influent from the weak acid resin hardening unit.

[0024] The third intermediate water storage tank is located between the weak acid resin hardening unit and the electrodialysis unit, and is used to store the effluent from the weak acid resin hardening unit or the influent from the electrodialysis unit.

[0025] In one possible implementation, the membrane pore size in the tubular membrane device is 0.05 μm.

[0026] In one possible implementation, the weak acid resin hardening unit comprises a macroporous weak acid resin.

[0027] The beneficial effects of the system provided by this utility model for treating high-hardness concentrated brine in the pharmaceutical industry are as follows: Compared with the prior art, the system pre-treats pharmaceutical wastewater through a front-end treatment unit to oxidize organic matter in the wastewater. An electrochemical hardening unit is connected to the front-end treatment unit. This unit generates flocculants through electrodes, which aggregate suspended particles, thereby removing some calcium and magnesium ions from the pre-treated pharmaceutical wastewater. A tubular membrane device is connected to the electrochemical hardening unit, filtering the precipitates in the wastewater after treatment to prevent clogging of subsequent equipment. A weak acid resin hardening unit is connected to the tubular membrane device for further calcium and magnesium ion removal from the filtered wastewater. An evaporator is connected to the weak acid resin hardening unit for evaporating the concentrated water discharged from the unit. The calcium and magnesium ions are removed again by a weak acid resin hardening unit, ensuring the removal effect and effectively alleviating the scaling phenomenon in the heat exchange tubes of the evaporator, thus ensuring the service life of the evaporator and making it highly practical. Attached Figure Description

[0028] Figure 1 This is a schematic diagram of a system for treating high-hardness concentrated brine in the pharmaceutical industry, provided as an embodiment of the present invention.

[0029] Explanation of reference numerals in the attached figures:

[0030] 10. Front-end treatment unit; 11. Raw material storage tank; 12. Ozone catalytic oxidation tank; 13. Ozone effluent tank; 20. Electrochemical hardening unit; 30. Tubular membrane equipment; 40. Weak acid resin hardening unit; 50. Evaporator; 60. Electrodialysis unit; 70. Reverse osmosis unit; 80. Sludge dewatering machine; 90. First intermediate storage tank; 100. Second intermediate storage tank; 110. Third intermediate storage tank; 120. Ozone source; 130. Reclaimed water tank. Detailed Implementation

[0031] To make the technical problems, technical solutions, and beneficial effects of this utility model clearer, the present utility model will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the present utility model and are not intended to limit the present utility model.

[0032] It should be noted that the terms "length", "width", "height", "thickness", "upper", "lower", "front", "rear", "left", "right", "vertical", "horizontal", "top", "bottom", "inner", "outer", "head", and "tail" indicate the orientation or positional relationship based on the orientation or positional relationship shown in the accompanying drawings. They are only for the convenience of describing this utility model and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, or be constructed and operated in a specific orientation. Therefore, they should not be construed as limitations on this utility model.

[0033] It should also be noted that, unless otherwise explicitly specified and limited, terms such as "installation," "connection," "fixing," and "setting" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral part; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or an indirect connection through an intermediate medium; they can refer to the internal communication of two components or the interaction between two components. Those skilled in the art can understand the specific meaning of the above terms in this utility model according to the specific circumstances.

[0034] Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. Additionally, "multiple" and "several" mean two or more, unless otherwise explicitly specified.

[0035] Please see Figure 1 This invention provides a system for treating high-hardness concentrated brine in the pharmaceutical industry. The system includes a front-end treatment unit 10, an electrochemical hardening unit 20, a tubular membrane device 30, a weak acid resin hardening unit 40, and an evaporator 50. The front-end treatment unit 10 is used for pretreatment of pharmaceutical wastewater. The electrochemical hardening unit 20 is connected to the front-end treatment unit 10 and generates a flocculant through electrodes to aggregate suspended particles. The tubular membrane device 30 is connected to the electrochemical hardening unit 20 and includes a filter membrane for cross-flow filtration, used to filter the pharmaceutical wastewater treated by the electrochemical hardening unit 20. The weak acid resin hardening unit 40 is connected to the tubular membrane device 30 and is used to remove calcium and magnesium ions from the filtered pharmaceutical wastewater. The evaporator 50 is connected to the weak acid resin hardening unit 40 and is used to evaporate the concentrated water discharged from the weak acid resin hardening unit 40.

[0036] In this embodiment, the pharmaceutical wastewater is first pretreated by the front-end treatment unit 10 to oxidize the organic matter in the wastewater. The electrochemical hardening unit 20 is connected to the front-end treatment unit 10. The electrochemical hardening unit 20 generates flocculants through electrodes. The flocculants are used to aggregate suspended particles, thereby aggregating suspended particles in the pretreated pharmaceutical wastewater. Specifically, iron or aluminum electrodes are used. When energized, the iron or aluminum electrodes generate iron or aluminum ions in the pharmaceutical wastewater, forming ferric hydroxide or aluminum hydroxide. Both ferric hydroxide and aluminum hydroxide have flocculation properties, which can enhance the precipitation performance of calcium carbonate (suspended particles) and magnesium hydroxide (suspended particles) in the pharmaceutical wastewater, facilitating the formation of precipitates.

[0037] The tubular membrane unit 30 is connected to the electrochemical hardening unit 20. The tubular membrane unit 30 performs cross-flow filtration on the precipitates in the pharmaceutical wastewater treated by the electrochemical hardening unit 20 (cross-flow filtration is a highly efficient membrane separation technology that reduces filter cake buildup through tangential flow of fluid to the membrane surface). The weak acid resin hardening unit 40 is connected to the tubular membrane unit 30 and is used to further remove calcium and magnesium ions from the pharmaceutical wastewater filtered by the tubular membrane unit 30. The evaporator 50 is connected to the weak acid resin hardening unit 40 and is used to evaporate the concentrated water discharged from the weak acid resin hardening unit 40.

[0038] This invention provides a system for treating high-hardness concentrated brine in the pharmaceutical industry. Compared with existing technologies, it pre-treats pharmaceutical wastewater through a front-end treatment unit 10 to oxidize organic matter in the wastewater. An electrochemical hardening unit 20 is connected to the front-end treatment unit 10. This unit generates flocculants through electrodes, which aggregate suspended particles, thereby removing some calcium and magnesium ions from the pre-treated wastewater. A tubular membrane device 30 is connected to the electrochemical hardening unit 20, filtering the precipitates in the wastewater after treatment to prevent clogging of subsequent equipment. A weak acid resin hardening unit 40 is connected to the tubular membrane device 30 for further calcium and magnesium ion removal from the filtered wastewater. An evaporator 50 is connected to the weak acid resin hardening unit 40 for evaporating the concentrated water discharged from the unit. The calcium and magnesium ions are removed again by the weak acid resin hardening unit 40, ensuring the removal effect of calcium and magnesium ions, effectively alleviating the scaling phenomenon in the heat exchange tube of evaporator 50, ensuring the service life of evaporator 50, and having good practicality.

[0039] In some embodiments, please refer to Figure 1The front-end treatment unit 10 includes a raw liquid holding tank 11 and an ozone catalytic oxidation unit. The raw liquid holding tank 11 is used to hold the pharmaceutical wastewater to be treated. The ozone catalytic oxidation unit is connected to the raw liquid holding tank 11 and is used to oxidize the organic matter in the pharmaceutical wastewater. In this embodiment, the pharmaceutical wastewater is held in the raw liquid holding tank 11, and the ozone catalytic oxidation unit is connected to the raw liquid holding tank 11, so that the pharmaceutical wastewater in the raw liquid holding tank 11 can be introduced into the ozone catalytic oxidation unit, whereby the ozone catalytic oxidation unit oxidizes the organic matter in the pharmaceutical wastewater to reduce the COD (chemical oxygen demand) of the pharmaceutical wastewater.

[0040] In some embodiments, please refer to Figure 1 The ozone catalytic oxidation unit includes an ozone catalytic oxidation tank 12 and an ozone effluent tank 13. The ozone catalytic oxidation tank 12 is connected to the raw solution storage tank 11 and to an ozone source 120, and is used for catalytic oxidation reactions. The ozone effluent tank 13 is connected to the ozone catalytic oxidation tank 12 and is used to temporarily store the effluent from the ozone catalytic oxidation tank 12. In this embodiment, ozone is introduced into the ozone catalytic oxidation tank 12 through the ozone source 120 to facilitate the oxidation of organic matter. A catalyst is also provided in the ozone catalytic oxidation tank 12 to improve ozone utilization, reduce ozone consumption, and conserve resources.

[0041] Furthermore, the thickness of the catalyst in the ozone catalytic oxidation tank 12 ranges from 2m to 3m. The ozone catalytic oxidation tank 12 also includes a backwashing process to prevent the filter media from caking. The wastewater from the backwashing process of the ozone catalytic oxidation tank 12 can be recycled into the original solution container 11, forming a resource recycling system and saving costs.

[0042] In some embodiments, please refer to Figure 1 The system for treating high-hardness concentrated brine in the pharmaceutical industry provided in this embodiment of the invention also includes a sludge dewatering machine 80, which is connected to the electrochemical hardening removal unit 20 and the ozone effluent tank 13. Specifically, the electrochemical hardening removal unit 20 is equipped with a dosing zone, an electrocoagulation zone, and an inclined plate sedimentation zone. The dosing zone is equipped with a pH meter, and liquid alkali or soda ash is added to control the pH of the pharmaceutical wastewater between 11 and 11.5 to form calcium carbonate or magnesium hydroxide precipitates. No chemical flocculants are added to the electrocoagulation zone; instead, iron or aluminum electrodes are used to generate flocculants. These flocculants are used to aggregate suspended particles, thereby removing some of the calcium and magnesium ions from the pharmaceutical wastewater. The inclined plate sedimentation zone contains suspended solids at a height of 0.9m to 1m, and a sludge hopper is installed at the bottom of the sedimentation zone for periodic sludge removal.

[0043] In this embodiment, the sludge in the electrochemical hardening unit 20 is discharged into the sludge dewatering machine 80, where it is dewatered. The water extracted from the sludge is then recycled to the ozone effluent tank 13, thus achieving resource recycling and saving costs. This reduces sediment in the water entering the tubular membrane device 30, ensuring the service life of the tubular membrane device 30.

[0044] In some embodiments, please refer to Figure 1 The system for treating high-hardness concentrated brine in the pharmaceutical industry provided in this embodiment of the invention also includes an electrodialysis unit 60 and a reverse osmosis unit 70. The electrodialysis unit 60 is connected to the weak acid resin hardening unit 40 and includes a concentrate tank, a desalination tank, and an electrode water tank. The concentrate tank is connected to the evaporator 50. The reverse osmosis unit 70 is connected to the desalination tank and is used to receive and recycle desalination water. Specifically, the electrode water refers to the water flow specifically flowing through the electrode chamber (near the anode or cathode) to rinse the electrode surface, remove reaction products (such as gases, precipitates, or corrosive substances), and prevent scale buildup or corrosion. During electrolysis, the electrodes generate heat; the electrode water cools the electrodes, dissipating heat. The electrode water maintains pH balance, preventing extreme pH levels near the electrodes (acidic at the anode and alkaline at the cathode) from affecting reaction efficiency. The electrode water also protects the electrodes, reducing scale buildup (such as CaCO3 adhesion) or corrosion (such as anodizing).

[0045] In this embodiment, the electrodialysis unit 60 includes a concentrate tank and a desalination tank, thereby separating the water produced by the weak acid resin hardening unit 40 into concentrate and desalination. The concentrate tank is connected to the evaporator 50, and the concentrate is directly evaporated in the evaporator 50. The desalination tank is connected to the reverse osmosis unit 70, which performs secondary concentrate and desalination separation on the water in the desalination tank. The desalination is recycled through the reclaimed water tank 130.

[0046] In some embodiments, please refer to Figure 1The system for treating high-hardness concentrated brine in the pharmaceutical industry provided in this embodiment of the invention further includes a first intermediate storage tank 90, a second intermediate storage tank 100, and a third intermediate storage tank 110. The first intermediate storage tank 90 is located between the electrochemical hardening unit 20 and the tubular membrane device 30, and is used to store the effluent from the electrochemical hardening unit 20 or the influent from the tubular membrane device 30. The second intermediate storage tank 100 is located between the tubular membrane device 30 and the weak acid resin hardening unit 40, and is used to store the effluent from the tubular membrane device 30 or the influent from the weak acid resin hardening unit 40. The third intermediate storage tank 110 is located between the weak acid resin hardening unit 40 and the electrodialysis unit 60, and is used to store the effluent from the weak acid resin hardening unit 40 or the influent from the electrodialysis unit 60. In this embodiment, the first intermediate water storage tank 90 is used to store the effluent from the electrochemical hardening unit 20 or the influent from the tubular membrane device 30, the second intermediate water storage tank 100 is used to store the effluent from the tubular membrane device 30 or the influent from the weak acid resin hardening unit 40, and the third intermediate water storage tank 110 is used to store the effluent from the weak acid resin hardening unit 40 or the influent from the electrodialysis unit 60, thereby allowing the water to be temporarily stored and recycled, avoiding waste.

[0047] Furthermore, the reverse osmosis unit 70 is connected to the second intermediate water storage tank 100 to introduce the concentrated water obtained from the separation into the second intermediate water storage tank, and then perform secondary hardening (removal of calcium and magnesium ions) through the weak acid resin hardening unit 40 to enhance the removal effect of calcium and magnesium ions.

[0048] In some embodiments, please refer to Figure 1 The membrane pore size in the tubular membrane device 30 is 0.05 μm. In this embodiment, the membrane material in the tubular membrane device 30 is PVDF (PVDF, also known as polyvinylidene fluoride, is a high-performance fluoropolymer with excellent chemical stability, heat resistance, weather resistance, mechanical strength, and unique electroactivity). The flow velocity inside the tubular membrane is greater than 2 m / s, the total hardness at the outlet is less than 150 mg / L, and the turbidity is less than 2 NTU (NTU stands for scattering turbidity unit, used to quantify the light scattering characteristics of suspended and colloidal particles in water).

[0049] In some embodiments, please refer to Figure 1 The weak acid resin hardening unit 40 includes a macroporous weak acid resin. In this embodiment, the macroporous weak acid resin has permanent pores (pore size range of 20nm~100nm), a large specific surface area, and can adsorb large molecules (such as proteins, pigments, etc.). The macroporous weak acid resin has strong anti-fouling ability and is suitable for high-turbidity solutions. Specifically, the macroporous weak acid resin is filled in a weak acid cation exchange resin tank, with a resin filling height ranging from 1.5m to 2m. The macroporous weak acid resin is used to remove calcium and magnesium ions from water and reduce water hardness.

[0050] The above description is only a preferred embodiment of the present utility model and is not intended to limit the present utility model. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present utility model should be included within the protection scope of the present utility model.

Claims

1. A system for treating high-hardness concentrated brine in the pharmaceutical industry, characterized in that, include: The front-end processing unit is used for pretreatment of pharmaceutical wastewater; An electrochemical hardening removal unit is connected to the front-end processing unit, and the electrochemical hardening removal unit generates flocculants for agglomerating suspended particles through electrodes; A tubular membrane device is connected to the electrochemical hardening unit, the tubular membrane device including a filter membrane for cross-flow filtration, used to filter pharmaceutical wastewater treated by the electrochemical hardening unit; A weak acid resin hardening unit is connected to the tubular membrane equipment and is used to remove calcium and magnesium ions from pharmaceutical wastewater filtered by the tubular membrane equipment. An evaporator, connected to the weak acid resin hardening unit, is used to evaporate the concentrated water discharged from the weak acid resin hardening unit.

2. The system for treating high-hardness concentrated brine in the pharmaceutical industry as described in claim 1, characterized in that, The front-end processing unit includes: The raw material container is used to hold pharmaceutical wastewater awaiting treatment. An ozone catalytic oxidation unit is connected to the original liquid container and is used to oxidize the organic matter in the pharmaceutical wastewater to be treated.

3. The system for treating high-hardness concentrated brine in the pharmaceutical industry as described in claim 2, characterized in that, The ozone catalytic oxidation unit includes: An ozone catalytic oxidation tank is connected to the raw liquid container and to an ozone source. The ozone catalytic oxidation tank is used to carry out catalytic oxidation reactions. An ozone effluent tank is connected to the ozone catalytic oxidation tank, and the ozone effluent tank is used to temporarily store the effluent from the ozone catalytic oxidation tank.

4. The system for treating high-hardness concentrated brine in the pharmaceutical industry as described in claim 3, characterized in that, The system for treating high-hardness concentrated brine in the pharmaceutical industry also includes a sludge dewatering machine, which is connected to the electrochemical hardening unit and the ozone effluent tank.

5. A system for treating high-hardness concentrated brine in the pharmaceutical industry as described in claim 1, characterized in that, The system for treating high-hardness concentrated brine in the pharmaceutical industry also includes: An electrodialysis unit is connected to the weak acid resin hardening unit. The electrodialysis unit includes a concentrate tank, a desalination tank, and an electrode tank; the concentrate tank is connected to the evaporator. The reverse osmosis unit is connected to the freshwater tank and is used to receive freshwater and recycle it.

6. The system for treating high-hardness concentrated brine in the pharmaceutical industry as described in claim 5, characterized in that, The system for treating high-hardness concentrated brine in the pharmaceutical industry also includes: The first intermediate water storage tank is located between the electrochemical hardening unit and the tubular membrane device, and is used to store the effluent from the electrochemical hardening unit or the influent from the tubular membrane device. The second intermediate water storage tank is located between the tubular membrane equipment and the weak acid resin hardening unit, and is used to store the effluent from the tubular membrane equipment or the influent from the weak acid resin hardening unit. The third intermediate water storage tank is located between the weak acid resin hardening unit and the electrodialysis unit, and is used to store the effluent from the weak acid resin hardening unit or the influent from the electrodialysis unit.

7. The system for treating high-hardness concentrated brine in the pharmaceutical industry as described in claim 1, characterized in that, The membrane pore size in the tubular membrane device is 0.05 μm.

8. The system for treating high-hardness concentrated brine in the pharmaceutical industry as described in claim 1, characterized in that, The weak acid resin hardening unit includes macroporous weak acid resin.

Images